Clinical cancer treatments nowadays still face the challenge of recurrence due to the residual cancer cells and minute lesions in surgeries or chemotherapies. To effectively address the problem, we introduce a strategy for constructing cancer cell nuclear-targeted copper sulfide nanoparticles (NPs) with a significant photothermal effect to completely kill residual cancer cells and prevent local cancer recurrence. The NPs could directly target the tumor cells and further enter the nucleus by the surface modification of RGD and TAT peptides. Under the irradiation of 980 nm near-infrared laser, the NPs rapidly increase the temperature of the nucleus, destroy the genetic substances, and ultimately lead to an exhaustive apoptosis of the cancer cells. In vivo experiments show that the designed NPs could effectively treat cancer and prevent the return of cancer with a single laser irradiation for 5 min. The photothermal therapy strategy with nuclear targeting for cancer therapy and anti-recurrence will provide more possibilities to develop efficient platforms for treating cancer.

Dihydroartemisinin (DHA) has attracted increasing attention as an anticancer agent. However, using DHA to treat cancer usually depends on the synergistic effects of exogenous components, and the loss of DHA during delivery reduces its effectiveness in cancer therapy. Reported herein is a programmed release nanoplatform of DHA to synergistically treat cancer with a Fe‐TCPP [(4,4,4,4‐(porphine‐5,10,15,20‐tetrayl) tetrakis(benzoic acid)] NMOF (nanoscale MOF) having a CaCO3 mineralized coating, which prevents DHA leakage during transport in the bloodstream. When the nanoplatform arrives at the tumor site, the weakly acidic microenvironment and high concentration of glutathione (GSH) trigger DHA release and TCPP activation, enabling the synergistic Fe2+‐DHA‐mediated chemodynamic therapy, Ca2+‐DHA‐mediated oncosis therapy, and TCPP‐mediated photodynamic therapy. In vivo experiments demonstrated that the nanoplatform showed enhanced anticancer efficiency and negligible toxicity.

Although ferroptosis therapy has been proven to be a promising strategy for cancer treatment, its efficacy still might be limited by insufficient H2O2 supply in tumor tissue. Herein, we designed a cancer cell membrane-cloaked cascade nanoreactor based on ferric metal–organic frameworks (MOF) and glucose oxidase (GOx) decoration for synergistic ferroptosis–starvation anticancer therapy. The GOx can catalyze glucose to generate sufficient H2O2 for ferroptosis therapy, and the glucose consumption caused by GOx can be utilized as another attractive cancer treatment strategy called starvation therapy. When the nanoreactor reached tumor sites, high concentration of GSH reduced Fe3+ to trigger structure collapse of MOF and release Fe2+ and GOx catalyzed the oxidation of glucose to generate H2O2. Then Fenton reaction happened between H2O2 and Fe2+ to produce hydroxyl radicals (•OH) and promoted ferroptosis therapy. With these cascade reactions, the synergistic ferroptosis–starvation anticancer therapy was realized. Furthermore, the cancer cell membrane endows the nanoreactor homologous targeting and immune escaping ability, which facilitated the nanoreactor to accumulate into tumor site with high efficiency. The nanoreactor exhibits high efficiency for tumor suppression with the in situ consumed and produced compounds, which can promote the development of precise cooperative cancer therapy with spatiotemporal controllability.

Tumor hypoxia typically occurs inside a solid tumor with an inadequate oxygen supply, sharply reducing the therapeutic efficiency of radiotherapy and significantly increasing the risk of local tumor recurrence.

A series of binary and ternary mixed LnMOFs with high stability showing potential applications in wide-range thermosensors and white LEDs are reported.